Fractures and bisphosphonates: reviving osteoporosis treatment uptake by identifying the genetic, material, and microstructural risk factors of atypical femur fractures

  • Ebeling, Peter (Primary Chief Investigator (PCI))
  • Zillikens, Maria Carola (Chief Investigator (CI))
  • Thakker, Rajesh V (Chief Investigator (CI))
  • Clifton-Bligh, Roderick (Chief Investigator (CI))
  • Sinnott, Richard (Chief Investigator (CI))
  • Zebaze, Roger MD (Chief Investigator (CI))
  • Seeman, Ego (Associate Investigator (AI))
  • Ng, Alvin (Associate Investigator (AI))
  • Chiang, Cherie (Associate Investigator (AI))
  • van den Bergh, Joop (Associate Investigator (AI))

Project: Research

Project Description

In patients with atypical femur fractures, we aim to:
1. Identify variants in previously unidentified genes that confer an increased risk of atypical femur fractures with antiresorptive therapy and their function.
2. Determine if genetic variants are present in exons related to monogenetic bone diseases, including those we have previously associated with AFF and examine their function.
3. Quantify abnormalities in bone remodeling, tissue mineral density and bone microstructure associated with atypical femur fractures.
Short titleTrAFFiC Study of Atypical Femur Fractures
AcronymTrAFFiC
StatusActive
Effective start/end date1/01/1831/12/21

Funding

  • National Health & Medical Research Council (NHMRC): AUD1,053,094.00